Multiple Myeloma Clinical Trials

• Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:

‣ MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria

⁃ Measurable disease at screening as assessed by central laboratory

• Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody

• Documented evidence of progressive disease (PD) or failure to achieve a response (that is partial response \[PR\] or better) to the last line of therapy based on investigator's determination of response by IMWG criteria

• Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent

• Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration